In the intricate world of Active Pharmaceutical Ingredient (API) synthesis, the selection of high-purity intermediates is paramount. These foundational molecules dictate the success of complex multi-step processes, directly influencing the quality, efficacy, and safety of the final drug product. Among the vital intermediates, 2,4-Difluoro-5-nitrobenzonitrile (CAS: 67152-20-9) has emerged as a compound of significant interest, particularly within the oncology research sector.

This specialized chemical, typically supplied as a light yellow powder, is recognized for its distinct molecular architecture, featuring a benzonitrile core functionalized with two fluorine atoms and a nitro group. With a molecular formula of C7H2F2N2O2 and a molecular weight of 184.100, its precise structure is key to its utility. The compound's reported purity of ≥98.0% is a critical attribute for its application in API synthesis, where stringent quality control is non-negotiable.

The primary application that drives the demand for 2,4-Difluoro-5-nitrobenzonitrile is its indispensable role in the synthesis of tankyrase inhibitors. These molecules are at the forefront of research into novel cancer therapies, specifically those aimed at inhibiting tumorigenesis. The fluorinated nature of the intermediate often enhances the pharmacokinetic and pharmacodynamic properties of the resulting drug candidates, making it a preferred choice for medicinal chemists.

When pharmaceutical companies and research institutions need to buy 2,4-Difluoro-5-nitrobenzonitrile, they seek not only purity but also a reliable supply chain. Identifying a reputable manufacturer in China or a trusted global supplier is crucial. These providers ensure consistent quality through rigorous testing and manufacturing protocols. Furthermore, understanding the price for bulk purchases is essential for efficient project budgeting and resource allocation.

The strategic importance of intermediates like 2,4-Difluoro-5-nitrobenzonitrile cannot be overstated. They serve as the bedrock upon which complex APIs are built. Therefore, ensuring a stable and high-quality supply from dedicated providers is a cornerstone of successful drug development. Companies can confidently advance their projects by partnering with suppliers who understand the demanding requirements of pharmaceutical synthesis.

In conclusion, 2,4-Difluoro-5-nitrobenzonitrile is a vital intermediate for the synthesis of advanced APIs, notably tankyrase inhibitors for cancer therapy. Its high purity, combined with reliable sourcing from experienced manufacturers and suppliers, ensures that pharmaceutical R&D can proceed with confidence. For any organization requiring this compound, prioritizing quality and dependable supply is key to unlocking therapeutic potential.